Loading…
China's leading maker of blood-glucose meters and diabetes home-monitoring devices for consumers.
China's leading maker of blood-glucose meters and diabetes home-monitoring devices for consumers.
Sells meters cheaply and earns on the test strips patients buy again and again, so every installed meter feeds repeat revenue. Most sales are in China through pharmacies and distributors, with exports a smaller part. It has added its own continuous glucose monitor, which reads sugar through a sensor worn on the skin.
In one line: China's LifeScan/Ascensia for glucose meters.
Moat: narrow (brand, distribution, installed base). Leading domestic brand with wide pharmacy distribution and installed meter base.
Headquarters: Changsha, Hunan, China · Founded: 2002 · Employees: 5,010
Size Sinocare (300298.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.58B, the 1556th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥19.05 on 6 Nov 2026.
Performance Over six months the shares gained 14.6%, against +2.4% for the median peer and -16.4% for the China market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 7.3% over the last twelve months (peer median +8.2%); the operating margin is 5.7% (peer median 14.5%).
Valuation It trades at 23.6× forward earnings against a peer median of 21.1× (8th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.2 points above its cost of capital (6.1% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.05B | CN¥4.64B | CN¥4.42B | CN¥4.04B | CN¥3.93B |
| Revenue growth | — | +5% | +9% | +3% | — |
| Gross profit | CN¥2.70B | CN¥2.14B | CN¥2.29B | CN¥2.03B | CN¥1.96B |
| EBITDA | n/a | CN¥396M | CN¥610M | CN¥548M | CN¥565M |
| Net income | CN¥253M | CN¥92.6M | CN¥326M | CN¥284M | CN¥447M |
| Free cash flow | CN¥392M | CN¥408M | CN¥446M | CN¥390M | CN¥366M |
| Capital expenditure | CN¥147M | CN¥199M | CN¥187M | CN¥347M | CN¥320M |
| Total debt | CN¥1.09B | CN¥960M | CN¥959M | CN¥1.22B | CN¥1.60B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sinocare 300298.SZ | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% |
| Andon Health 002432.SZ | $3.60B | -29% | -30% | -26% | 15.0× | -7.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300298.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.1% | +0.3% | 4th highest of 21 |
| 6-month return | +14.6% | +2.4% | 6th highest of 20 |
| Distance from 52-week high | -6.2% | -21.2% | 2nd highest of 21 |
| Revenue growth (TTM) | +7.3% | +8.2% | 11th highest of 21 |
| Operating margin | 5.7% | 14.5% | 6th lowest of 21 |
| Forward P/E | 23.6× | 21.1× | 8th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 10.8% | 18.0% | 6th least demanding of 15 |
| Growth delivered (Del g) | +18.3% | +11.3% | 6th highest of 15 |
| Hurdle (Req g minus delivered) | -7.5 pp | +0.3 pp | 4th least demanding of 15 |
| ROIC minus cost of capital | +2.2 pp | +2.5 pp | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% | +18.3% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 17.2× | 3.1% | +23.4% |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 7.7× | 22.3% | -6.0% |
| NIPRO 8086.T | Japan | $1.55B | -9% | +3% | 6% | 14.9× | n/a | n/a |
| NovoCure NVCR | United States | $1.55B | -26% | +13% | -17% | n/a | n/a | n/a |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 17.6× | -2.1% | +3.3% |
| Vitrolife VITR.ST | Sweden | $1.63B | +14% | -2% | 19% | 27.6× | 22.0% | +22.5% |
| CONMED CNMD | United States | $1.53B | +40% | +2% | 2% | 11.1× | 32.4% | +9.8% |
| Molbio Diagnostics MOLBIO.NS | India | $1.63B | n/a | +35% | 17% | n/a | n/a | n/a |
| Rigaku 268A.T | Japan | $1.66B | -57% | +5% | 15% | 20.4× | 18.8% | +14.5% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.69B | +124% | +3% | 49% | 52.0× | 17.9% | +12.7% |
| Beijing Balance Medical Technology 688198.SS | China | $1.47B | -26% | +10% | 28% | 46.6× | 22.6% | +27.6% |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | n/a | n/a | n/a |
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% | +23.6% |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 52.1× | 18.1% | +25.8% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 21.8× | 9.8% | +7.7% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% | +8.3% |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 14.6× | -3.2% | -1.0% |